Evaluating quality of life after treatment for rectal cancer
Radiation or Chemoradiation Followed by Surgery in Patients With Rectal Cancer
Ludwig-Maximilians - University of Munich · NCT03731130
This study looks at how treatment for rectal cancer affects the quality of life for patients who receive radiation or chemotherapy before surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ludwig-Maximilians - University of Munich (other) |
| Drugs / interventions | Radiation |
| Locations | 1 site (Munich, Bavaria) |
| Trial ID | NCT03731130 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the quality of life in patients with rectal cancer who undergo neoadjuvant radiation or chemoradiation followed by surgery. It will utilize standardized EORTC questionnaires to evaluate longitudinal quality of life, functional outcomes, oncological outcomes, and toxicity. The study will track both acute and late side effects of treatment and analyze correlations between physician and patient-reported outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with histologically proven rectal cancer who are eligible for neoadjuvant radiation or chemoradiation therapy.
Not a fit: Patients under 18 years old, those with distant metastases, or those who have received prior systemic therapy for rectal cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the quality of life and treatment outcomes for rectal cancer patients, potentially guiding future treatment approaches.
How similar studies have performed: Other studies have successfully evaluated quality of life in cancer patients using similar methodologies, indicating that this approach is well-established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * histologically proven rectal Cancer without distant metastases * indication for neoadjuvant Radiation or chemoradiation therapy according to multidiciplinary Evaluation * age \>=18 years * written informed consent * ability to answer the standardized questionaires according to the treating physician Exclusion Criteria: * age \< 18 years * prior systemic therapy with regard to rectal Cancer * distant metastasis * second malignancy
Where this trial is running
Munich, Bavaria
- Department of Radiation Oncology, University Hospital, LMU Munich — Munich, Bavaria, Germany (RECRUITING)
Study contacts
- Principal investigator: Falk Roeder, MD — Ludwig-Maximilians Universität München
- Study coordinator: Falk Roeder, MD
- Email: Falk.Roeder@t-online.de
- Phone: +49 89 4400
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Rectal Cancer, Quality of Life, Radiation Therapy, Chemoradiation, rectal cancer, quality of life, neoadjuvant, radiation therapy